Science Explorer Back to mapMap
Discussion
Institution · Selecta Biosciences (United States)

Most cited papers from Selecta Biosciences (United States)

Selecta Biosciences (United States)

What are the most cited papers from Selecta Biosciences (United States)?

The most cited paper from Selecta Biosciences (United States) is "Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance" (Roberto Maldonado, Robert A. LaMothe, Joseph D. Ferrari et al., 2014), with 441 citations. Next come "Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration" (266) and "Microfluidics-free single-cell genomics with templated emulsification" (228).

Showing 50 of 72 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance Roberto Maldonado, Robert A. LaMothe, Joseph D. Ferrari et al. · Proceedings of the National Academy of Sciences Open access 29 Dec 2014 441
2 Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration Amine Meliani, Florence Boisgérault, Romain Hardet et al. · Nature Communications Open access Oct 2018 266
3 Microfluidics-free single-cell genomics with templated emulsification Iain C. Clark et al. · Nature Biotechnology Open access 6 Mar 2023 228
4 Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles Takashi Kishimoto, Joseph D. Ferrari, Robert A. LaMothe et al. · Nature Nanotechnology 29 Jul 2016 200
5 Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance Takashi Kishimoto, Roberto Maldonado · Frontiers in Immunology Open access 20 Feb 2018 171
6 Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release Petr O. Ilyinskii, Christopher J. Roy, Conlin P. O’Neil et al. · Vaccine Open access Mar 2014 168
7 Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis Robert A. LaMothe, Pallavi N. Kolte, Trinh Phuong Vo et al. · Frontiers in Immunology Open access 2 Mar 2018 112
8 Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates Christopher C. Fraser, David H. Altreuter, Petr O. Ilyinskii et al. · Vaccine Open access 26 Feb 2014 84
9 TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25 Elizabeth A. Thompson, Sebastian Ols, Kazutoyo Miura et al. · JCI Insight Open access 16 May 2018 76
10 Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies Takashi Kishimoto · Frontiers in Immunology Open access 20 May 2020 62
11 Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia Earl Sands, Alan Kivitz, Wesley H. DeHaan et al. · Nature Communications Open access 12 Jan 2022 60
12 Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles Petr O. Ilyinskii, Alicia M. Michaud, Christopher J. Roy et al. · Science Advances Open access 24 Feb 2021 55
13 Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity Ronit Mazor, Emily M. King, Masanori Onda et al. · Proceedings of the National Academy of Sciences Open access 8 Jan 2018 50
14 Detection of viral RNAs at ambient temperature via reporter proteins produced through the target-splinted ligation of DNA probes Elizabeth A. Phillips, Adam D. Silverman, Aric Joneja et al. · Nature Biomedical Engineering Open access 4 May 2023 44
15 ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia Petr O. Ilyinskii, Alicia M. Michaud, Gina L. Rizzo et al. · Molecular Therapy — Methods & Clinical Development Open access 16 Jul 2021 39
16 Tolerogenic Nanoparticles Impacting B and T Lymphocyte Responses Delay Autoimmune Arthritis in K/BxN Mice Amrita Srivastava, Britni M. Arlian, Lijuan Pang et al. · ACS Chemical Biology Open access 26 May 2021 30
17 Query relaxation by structure and semantics for retrieval of logical Web documents Wen-Syan Li, K. Selçuk Candan, Quoc Vu et al. · IEEE Transactions on Knowledge and Data Engineering Jul 2002 30
18 Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles Petr O. Ilyinskii, Christopher J. Roy, Julie LePrevost et al. · Frontiers in Immunology Open access 25 May 2021 29
19 Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease Takashi Kishimoto, Max Fournier, Alicia M. Michaud et al. · Journal of Autoimmunity Open access 14 Oct 2023 28
20 The proteomics bottleneck: strategies for preliminary validation of potential biomarkers and drug targets Steven Bodovitz · Trends in biotechnology 24 Nov 2003 27
21 A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease Han Hyuk Lim, Haiqing Yi, Takashi Kishimoto et al. · Molecular Genetics and Metabolism Reports Open access 23 Jul 2017 26
22 Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110) Alan Kivitz, Wesley H. DeHaan, Rehan Azeem et al. · Rheumatology and Therapy Open access 17 Apr 2023 25
23 Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector Giulia De Sabbata, Florence Boisgérault, Corrado Guarnaccia et al. · Molecular Therapy — Methods & Clinical Development Open access 16 Nov 2020 25
24 The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout Herbert S. B. Baraf, Puja P. Khanna, Alan Kivitz et al. · Lara D. Veeken Open access 13 Jul 2023 23
25 A New Natural Defense Against Airborne Pathogens David Albert Edwards, Anthony James Hickey, Richard P. Batycky et al. · QRB Discovery Open access 2020 22
26 Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy Minggang Fang, Alexander G. Allen, Chong Luo et al. · Frontiers in Immunology Open access 30 Aug 2024 21
27 Genome-wide identification of PTI1 family in Setaria italica and salinity-responsive functional analysis of SiPTI1–5 Yongguan Huangfu, Jiaowen Pan, Zhen Li et al. · BMC Plant Biology Open access 3 Jul 2021 21
28 Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy Petr O. Ilyinskii, Grigoriy I. Kovalev, Conlin P. O’Neil et al. · PLoS ONE Open access Jun 2018 20
29 Real-Time, Multiplexed SHERLOCK for in Vitro Diagnostics Jennifer M Peña, Brendan J Manning, Xiang Li et al. · Journal of Molecular Diagnostics Open access 23 Apr 2023 19
30 Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi et al. · Molecular Cancer Therapeutics Open access 23 Dec 2019 19
31 Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia Cheryl A.C. Peretz et al. · Nature Communications Open access 18 Sep 2024 17
32 Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents Petr O. Ilyinskii, Christopher J. Roy, Alicia M. Michaud et al. · PNAS Nexus Open access Nov 2023 16
33 Experimental strategies to improve drug-target identification in mass spectrometry-based thermal stability assays Clifford G. Phaneuf, Konstantin Aizikov, Dmitry Grinfeld et al. · Communications Chemistry Open access 6 Apr 2023 14
34 Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy Nicholas D. Weber, Leticia Odriozola, Irene Ros‐Gañán et al. · JHEP Reports Open access 24 Feb 2023 14
35 DFT Study on the His-Tag Binding Affinity of Metal Ions in Modeled Hexacationic Metal Complexes Alparslan Numan Yildiz, Esra E. Kasapbasi, Zeynep Yurtsever et al. · ACS Omega Open access 8 Nov 2024 12
36 A Platform for Controlled Template-Independent Enzymatic Synthesis of RNA Oligonucleotides and Therapeutics Daniel J. Wiegand, Jonathan Rittichier, Ella Meyer et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 29 Jun 2023 12
37 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one Andreas Lundqvist et al. · Journal for ImmunoTherapy of Cancer Open access1,762 authors Nov 2016 11
38 Eilat virus (EILV) causes superinfection exclusion against West Nile virus (WNV) in a strain-specific manner in Culex tarsalis mosquitoes Renuka Elizabeth Joseph, Jovana Bozic, Kristine Werling et al. · Journal of General Virology Open access 27 Aug 2024 10
39 Bioanalytical Challenges and Unique Considerations to Support Pharmacokinetic Characterization of Bispecific Biotherapeutics Mark Ma, Kelly S. Colletti, Tong‐Yuan Yang et al. · Bioanalysis Mar 2019 10
40 Repeated dosing of AAV-mediated liver gene therapy in juvenile rat and mouse models of Crigler-Najjar syndrome type I Xiaoxia Shi, Giulia Bortolussi, Fanny Collaud et al. · Molecular Therapy — Methods & Clinical Development Open access 30 Oct 2024 8
41 Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-naïve HIV-1 Subtype C-infected patients in Botswana Dorcas Maruapula, Iain J. MacLeod, Sikhulile M. Moyo et al. · AAS Open Research Open access 28 Sep 2020 7
42 Development of circular AAV cargos for targeted seamless insertion with large serine integrases Brett Estes, Nisha Gandhi, Jessica R Von Stetina et al. · Molecular Therapy — Methods & Clinical Development Open access 14 May 2025 6
43 Single-cell analysis of the nervous system at small and large scales with instant partitions Paul W. Frazel, K Fricano-Kugler, AA May-Zhang et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 15 Jul 2023 6
44 SAT0402 SEL-212 PHASE 2 CLINICAL STUDY IN SYMPTOMATIC GOUT PATIENTS: IMMTOR TOLEROGENIC NANOPARTICLES COMBINED WITH PEGADRICASE MITIGATES IMMUNOGENICITY AND ENABLES SUSTAINED REDUCTION OF SERUM URIC ACID LEVELS, LOW RATE OF GOUT FLARES AND MONTHLY DOSING Stephen Smolinski, Alan Kivitz, Wesley H. DeHaan et al. · Annals of the Rheumatic Diseases Open access Jun 2019 6
45 Meta-atlas of Juvenile and Adult Enteric Neuron scRNA-seq for Dataset Comparisons and Consensus on Transcriptomic Definitions of Enteric Neuron Subtypes Joseph T. Benthal, Aaron A. May‐Zhang, E. Michelle Southard‐Smith · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 4 Nov 2024 5
46 P109 Clinical development of a novel strategy to mitigate biologic immunogenicity: monthly dosing of a pegylated uricase with SVP-R enables sustained reduction of serum uric acid (SUA) levels by mitigating formation of anti-drug antibodies (ADAS) Emma M. Sands, Alan Kivitz, Wesley H. DeHaan et al. · Annals of the Rheumatic Diseases Open access 22 Feb 2018 5
47 Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk Stratification Cheryl A.C. Peretz, Vanessa Elaine Kennedy, Anushka Walia et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 18 May 2023 4
48 Nanoparticle-Based Nicotine Vaccine Petr O. Ilyinskii, Lloyd P. M. Johnston Book chapter 18 Dec 2015 4
49 Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies Matthew Li, Brent A. Morse, Sadik H. Kassim · Expert Opinion on Biological Therapy 14 Jul 2022 3
50 ImmTORTM to amplify the efficacy and reduce immunogenicity of biologics Carsten Brunn, Takashi Kishimoto · Emerging Topics in Life Sciences 13 Aug 2021 3

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.